Ocugen Shares Rise 5% After $7.1 Million Licensing Deal with Celairis for OCU400
Ocugen partners with Celairis for OCU400 gene therapy in Australia and ASEAN markets, securing up to $7.1 million in payments plus a 50% gross profit share.
ALFA USA News
Straight from the SEC filing
Every SEC filing by Ocugen, Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (10 Nov 2026). Not a valuation or a recommendation.
Down 1.8% over the last month ($0.79 on 19 Oct → $0.77 on 16 Nov). Daily closing prices. Source: Yahoo Finance.
| 19 Oct | $0.79 |
|---|---|
| 20 Oct | $0.81 |
| 21 Oct | $0.81 |
| 22 Oct | $0.79 |
| 23 Oct | $0.74 |
| 26 Oct | $0.71 |
| 27 Oct | $0.76 |
| 28 Oct | $0.78 |
| 29 Oct | $0.74 |
| 30 Oct | $0.70 |
| 2 Nov | $0.72 |
| 3 Nov | $0.74 |
| 4 Nov | $0.88 |
| 5 Nov | $0.82 |
| 6 Nov | $0.93 |
| 9 Nov | $0.97 |
| 10 Nov | $0.95 |
| 11 Nov | $0.96 |
| 12 Nov | $0.87 |
| 13 Nov | $0.83 |
| 16 Nov | $0.77 |
Ocugen partners with Celairis for OCU400 gene therapy in Australia and ASEAN markets, securing up to $7.1 million in payments plus a 50% gross profit share.
Ocugen (OCGN) signs a $259 million licensing deal with Roots Pharmaceutical for its OCU400 gene therapy in the MENA region, featuring a 22% net sales royalty.
Track Ocugen, Inc. live
Get the next Ocugen, Inc. SEC filing seconds after it lands.